一种抗猫传染性腹膜炎病毒的药物组合、制剂及其应用
The combination of entrectinib with GS441524 or GC376 addresses the treatment challenges of feline infectious peritonitis by inhibiting the programmed-1 ribosomal frameshift and 3CL protease of coronaviruses, achieving highly effective viral suppression and prevention while avoiding drug resistance issues.
CN122398809APending Publication Date: 2026-07-17WEST CHINA HOSPITAL SICHUAN UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- WEST CHINA HOSPITAL SICHUAN UNIV
- Filing Date
- 2026-06-22
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Current technologies are insufficient to effectively treat feline infectious peritonitis, and existing antiviral drugs have limited efficacy and drug resistance issues.
Method used
The combination of entrectinib with compounds GS441524 and/or GC376 synergistically enhances antiviral efficacy by inhibiting the programmed-1 ribosomal frameshift and 3CL protease of coronaviruses, avoiding drug resistance caused by viral gene mutations.
Benefits of technology
It significantly enhances the inhibitory effect on feline infectious peritonitis virus, reduces the risk of drug resistance, and provides an effective treatment and prevention strategy.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122398809A_ABST
Abstract
本发明涉及抗病毒药物技术领域，提供了一种抗猫传染性腹膜炎病毒的药物组合、制剂及其应用。该药物组合包括恩曲替尼，以及化合物GS441524和 / 或化合物GC376。通过恩曲替尼（Entrectinib）与化合物GS441524、化合物GC376联用，表现出显著增强的抗猫传染性腹膜炎病毒（FIPV）效果，并具有显著的协同增强效应；且该药物组合应用于抗猫传染性腹膜炎病毒时，对FIPV的变异不敏感，不易产生耐药性问题，具有良好的临床用药开发前景，为治疗、预防猫传染性腹膜炎的用药提供了新的选择。
Need to check novelty before this filing date? Find Prior Art